EuroBiotech: More Articles of Note

Newspapers

> Transgene raised €14.4 million ($16.9 million) from U.S. and European investors. The financing extends the French immuno-oncology player’s financial runway out to the middle of 2019. Release  

> ProQr priced a $20 million public offering. The Dutch biotech plans to split the cash fairly evenly between three pipeline prospects: QR-110, QR-313 and QRX-421. Statement

> Mereo BioPharma received EMA PRIME designation for BPS-804 in osteogenesis imperfecta. The regulatory status positions the ex-Novartis’ asset to benefit from an accelerated assessment if it makes it as far as a filing for approval. Release

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Immunocore posted data on its bispecific T cell redirector IMCgp100 in patients with metastatic uveal melanoma. Two of the 19 patients in the intra-patient dose escalation had objective responses to treatment. But, despite that low rate, 73% were alive after one year. That compares favorably to the survival rates in patients treated with other regimens. Statement

> Motif Bio secured up to $20 million in debt financing. The facility, which has a 10% interest rate tied to the U.S. prime rate, gives Motif Bio the cash to prepare for the planned commercialization of its antibiotic in 2019. Release

> The full exercising of the underwriters’ option on additional shares pushed Erytech’s IPO haul up to $144 million. That sees Erytech join Ablynx, which raised $230 million, toward the top of the list of the largest Nasdaq biotech IPOs of the year. Statement

Suggested Articles

What a difference a day makes in biotech.

A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing.

A drug developed at Temple restores a mechanism in brain cells that prevents the toxic buildup of the proteins amyloid beta and tau in Alzheimer's.